ABSTRACT
Introduction Recently, fluid collected from the heat-and-moisture-exchange filters, which are commonly used in most mechanically ventilated patients under intravenous sedation, has been reported as a potential surrogate for fluid in the distal airspace. Therefore, collection of this fluid represents a promising, non-invasive method for sampling the distal airspace in patients with acute respiratory distress syndrome (ARDS) and for facilitating a mechanistic understanding of this devastating disease. The current study protocol was constructed to assess whether this fluid could be sampled from a dedicated device (Anaesthetic Conserving Device [AnaConDa-S], Sedana Medical, Danderyd, Sweden) used to deliver inhaled sevoflurane for sedation in patients with ARDS.
Methods and analysis A total of 30 adult patients within 24 hours of meeting the Berlin criteria for moderate-severe ARDS and receiving inhaled sevoflurane as standard sedation in participating centres will be eligible for inclusion into this investigator-initiated, exploratory, prospective, bicentre study. After at least 12 h of inhaled sedation, a sample of directly aspirated, undiluted pulmonary oedema fluid will be collected concurrently with fluid from the AnaConDa-S device. Levels of proinflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α and sTNFr-1) and markers of lung endothelial (Ang-2) and epithelial (sRAGE) injury will be measured in both fluids by Multiplex. The primary endpoint is the correlation between protein markers (IL-1β, IL-6, IL-8, TNF-α, sTNFr-1, Ang-2 and sRAGE) measured in the undiluted pulmonary oedema fluid versus the AnaConDa-S fluid.
Ethics and dissemination The study was approved by the appropriate ethics committee (CPP Est I). Informed consent is required. The fluid collection from the AnaConDa-S has potential to foster our understanding of the potential effects of inhaled sedation in clinical ARDS and to open up novel perspectives for prognostic and predictive enrichment in future trials. The results will be published in a peer-reviewed journal.
Registration number NCT03964155.
Competing Interest Statement
No specific funding has been received for this study apart from institutional funds, and the authors declare that there is no conflict of interest regarding the publication of this study protocol. MJ is a principal investigator of the SEvoflurane for Sedation in ARds (SESAR) (ClinicalTrials.gov Identifier: NCT04235608) and the ISCA study, which are co-funded and funded, respectively, by grants from Sedana Medical. JMC and MJ received fees from Sedana Medical for participation in a scientific advisory panel in 2019; MJ received consulting fees from Abbvie in 2020.
Clinical Trial
Registration number: NCT03964155
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03964155
Funding Statement
No specific funding has been received for this study apart from institutional funds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the French ethics committee CPP Est I and ANSM in January 2019 (approval numbers RBHP 2018 JABAUDON 2 - ANAISS 2018-A02596-49).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: No specific funding has been received for this study apart from institutional funds, and the authors declare that there is no conflict of interest regarding the publication of this study protocol. MJ is a principal investigator of the SEvoflurane for Sedation in ARds (SESAR) (ClinicalTrials.gov Identifier: NCT04235608) and the ISCA study, which are co-funded and funded, respectively, by grants from Sedana Medical. JMC and MJ received fees from Sedana Medical for participation in a scientific advisory panel in 2019; MJ received consulting fees from Abbvie in 2020.
Data Availability
All data related to this study protocol will be made available upon request.